Faculty of Medical Sciences

Staff Profile

Dr Phil Elstob

CRT Business Development Executive



Phil Elstob is the Business Development Manager for the Northern Institute for Cancer Research, a joint position between the Faculty of Medical Sciences Enterprise Team and Cancer Research Technology Limited (the technology transfer arm of the charity Cancer Research UK).


Roles and Responsibilities

Phil is responsible for a strategic alliance between the University and Cancer Research Technology that focuses on the identification, protection, development and commercialisation of novel cancer technologies. Specific activities include:

·         Sourcing and evaluating potential new projects (cancer therapies and diagnostics/prognostics)

·         Identifying/securing funding for and managing the development of cancer technologies (mainly small molecule drug discovery projects)

·         Intellectual property assessment (patentability and freedom to operate), patent filing and prosecution

·         Developing and delivering marketing and commercialisation strategies

·         Structuring, negotiation and execution of a wide range of intellectual property agreements, and the use of financial models for deal valuation



After completing a first degree in Medical Biochemistry (BSc) at Leicester University, which included a year in industry at GlaxoSmithKline,  Phil went on to do a PhD at the MRC’s National Institute for Medical Research (Mill Hill) in developmental biology. In 2001 he joined Cancer Research Technology’s London office and moved to Newcastle in 2006 to take up a joint position with Newcastle University. Phil is employed by CRT, where he is a Business Development Executive, and is a guest member of staff in the University Faculty of Medical Sciences.  During his time in Newcastle Phil spent 18 months as interim Chief Executive Officer of Demuris Limited, a University spin out company founded by Professor Jeff Errington.



·         Technology sourcing & assessment

·         IP & patent management

·         Licensing/partnering with pharma/biotech

·         Commercial and R&D strategy

·         Small molecule drug discovery